Letrozole Pretreatment With Misoprostol Induction of Abortion In First-Trimester Missed Miscarriage
Letrozole Pretreatment With Misoprostol for Induction of Abortion In First-Trimester Missed Miscarriage Among Women With One or More Previous Cesarean Deliveries.: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age less than 64 days gestation (<9 wks).
- Hemoglobin >10 g/dL.
- BMI between 18.5 kg/m2 and 25 kg/m2.
- Missed abortion.
- previous one or more cesarean delivaries
Exclusion Criteria:
- Molar pregnancy.
- Fibroid uterus.
- Uterine anomalies.
- Coagulopathy.
- Medical disorder that contraindicate induction of abortion (e.g. heart failure).
- Previous attempts for induction of abortion in the current pregnancy.
- Allergy to misoprostol or letrozole.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: study group
3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
|
Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion |
|
Placebo Comparator: control group
three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
|
Drug: Placebo placebo for 3 days Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
induction to abortion time
Time Frame: 6 hours
|
induction to abortion time
|
6 hours
|
|
Incidence of complete miscarriage
Time Frame: 6 hours
|
Incidence of complete miscarriage
|
6 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Need for surgical evacuation of the products of conception
Time Frame: 6 hours
|
Need for surgical evacuation of the products of conception
|
6 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Abortion, Spontaneous
- Abortion, Missed
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Gastrointestinal Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Reproductive Control Agents
- Anti-Ulcer Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Oxytocics
- Letrozole
- Misoprostol
Other Study ID Numbers
Other Study ID Numbers
- letrozole pretreatment
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Missed Abortion
-
NCT05001061Not yet recruiting
-
NCT04981457Active, not recruiting
-
NCT04590482Unknown
-
NCT03081104Unknown
-
NCT03584698Completed
-
NCT02342002TerminatedPregnancy | Missed Abortion
-
NCT07526064Not yet recruiting
-
NCT04593108Unknown
-
NCT04217265Unknown
Clinical Trials on letrozole then misoprostol
-
NCT04217265Unknown
-
NCT07636317CompletedMissed Abortion | Letrozole | Misoprostol | Induction
-
NCT07160855RecruitingMiscarriage in First Trimester | Missed Miscarriage
-
NCT04593108Unknown
-
NCT02825966Completed
-
NCT03228121WithdrawnCOPD | Chronic Bronchitis | Emphysema or COPD
-
NCT07171047CompletedHealthy | Performance | Athlete | Well-trained Athletes
-
NCT05392803CompletedPhantom Limb Pain | Residual Limb Pain
-
NCT05207644Completed